US Stock MarketDetailed Quotes

ROIV Roivant Sciences

Watchlist
  • 12.140
  • +0.020+0.17%
Trading Dec 4 15:50 ET
8.84BMarket Cap2.08P/E (TTM)

About Roivant Sciences Company

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Company Profile

SymbolROIV
Company NameRoivant Sciences
Listing DateDec 14, 2020
Founded2021
CEOMr. Matthew Gline
MarketNASDAQ
Employees908
Fiscal Year Ends03-31
Address50 Broadway,7th Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeSW1H 0BD
Phone44-207-400-3347

Company Executives

  • Name
  • Position
  • Salary
  • Matthew Gline
  • Chief Executive Officer and Director
  • 738.19K
  • Dr. Eric Venker, M.D.,Pharm.D.
  • President and Chief Operating Officer
  • --
  • Richard Pulik
  • Chief Financial Officer
  • 5.15M
  • Dr. Mayukh Sukhatme
  • President, Chief Investment Officer and Director
  • 574.56K
  • Rakhi Kumar
  • Chief Accounting Officer
  • 4.33M
  • Ilan Oren
  • Chairman of the Board
  • 488.49K
  • James C. Momtazee
  • Independent Director
  • 459.24K
  • Meghan M. Fitzgerald, Ph.
  • Independent Director
  • 941.68K
  • Keith Manchester, M.D.
  • Independent Director
  • 442.59K
  • Daniel Gold
  • Independent Director
  • 449.24K
  • Melissa B. Epperly
  • Independent Director
  • 444.24K